Charles River Laboratories International (CRL) Payables (2009 - 2026)

Charles River Laboratories International has reported Payables for 18 years, with the latest figure at $141.0 million in Q2 2026.

• On a quarterly basis, Payables fell 3.3% year-over-year to $141.0 million in Q2 2026; TTM through Jun 2026 was $141.0 million, a 3.3% decrease from a year earlier, with the FY2025 full-year figure at $148.8 million, up 6.03% from the prior year.
• Payables was $141.0 million for Q2 2026 at Charles River Laboratories International, up from $134.0 million in the prior quarter.
• The five-year high for Payables was $226.0 million in Q1 2022, with the low at $120.0 million in Q2 2023.
• Average Payables over 5 years is $156.6 million, with a median of $143.4 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Payables surged 90.56% in 2022, then slumped 46.9% in 2023.
• Over 5 years, Payables stood at $205.9 million in 2022, then declined by 17.96% to $168.9 million in 2023, then declined by 16.93% to $140.3 million in 2024, then grew by 6.03% to $148.8 million in 2025, then decreased by 5.25% to $141.0 million in 2026.
• The last three Payables figures came in at $141.0 million (Q2 2026), $134.0 million (Q1 2026), and $148.8 million (Q4 2025), per Business Quant data.